Literature DB >> 12217815

Nuclear factor k B is activated in myelodysplastic bone marrow cells.

Cristina Sanz, Carlos Richard, Felipe Prosper, Jos Luis Fernandez-Luna.   

Abstract

We describe a significant increase in the DNA binding activity of nuclear factor-kappa B (NF kappa B) in bone marrow cells from patients with myelodysplastic syndrome (MDS) compared with normal donor cells. Furthermore, MDS samples with increased NFkappaB activity consistently showed higher mRNA levels of NFkappaB-regulated cytokines.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12217815

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  9 in total

1.  Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.

Authors:  Jian Huang; Ting Ding; Min Yang; Hui Liu; Xin Sun; Jie Jin
Journal:  Int J Hematol       Date:  2011-03-31       Impact factor: 2.490

2.  An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.

Authors:  May Daher; Juliana Elisa Hidalgo Lopez; Jasleen K Randhawa; Kausar Jabeen Jabbar; Yue Wei; Naveen Pemmaraju; Gautam Borthakur; Tapan Kadia; Marina Konopleva; Hagop M Kantarjian; Katherine Hearn; Zeev Estrov; Steven Reyes; Carlos E Bueso-Ramos; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2017-06-09       Impact factor: 10.047

3.  Frequency of inherited variants in the MEFV gene in myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Serkan Celik; Cagatay Oktenli; Emrah Kilicaslan; Fatih Tangi; Ozkan Sayan; H Onur Ozari; Osman Ipcioglu; Yavuz S Sanisoglu; M Hakan Terekeci; Alev A Erikci
Journal:  Int J Hematol       Date:  2012-02-18       Impact factor: 2.490

4.  NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).

Authors:  Daniella M B Kerbauy; Vladimir Lesnikov; Nissa Abbasi; Sudeshna Seal; Bart Scott; H Joachim Deeg
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

5.  Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs.

Authors:  Tomoya Muto; Callum S Walker; Kwangmin Choi; Kathleen Hueneman; Molly A Smith; Zartash Gul; Guillermo Garcia-Manero; Averil Ma; Yi Zheng; Daniel T Starczynowski
Journal:  Nat Immunol       Date:  2020-04-20       Impact factor: 25.606

6.  Downregulation of hTERT: an important As2O3 induced mechanism of apoptosis in myelodysplastic syndrome.

Authors:  Weilai Xu; Yungui Wang; Hongyan Tong; Wenbin Qian; Jie Jin
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

Review 7.  Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells.

Authors:  Shayda Hemmati; Tamanna Haque; Kira Gritsman
Journal:  Front Oncol       Date:  2017-11-13       Impact factor: 6.244

Review 8.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

9.  Reduction of c-Fos via Overexpression of miR-34a Results in Enhancement of TNF- Production by LPS in Neutrophils from Myelodysplastic Syndrome Patients.

Authors:  Yayoi Shikama; Meiwan Cao; Tomoyuki Ono; Xiaomin Feng; Hideyoshi Noji; Hideo Kimura; Kazuei Ogawa; Yuko Suzuki; Kazuhiko Ikeda; Yasuchika Takeishi; Junko Kimura
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.